Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by May, J.
Right arrow Articles by French, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by May, J.
Right arrow Articles by French, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 42, 189-197, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

Glycopeptide tolerance in Staphylococcus aureus

J May, K Shannon, A King and G French
Department of Microbiology, UMDS, St Thomas' Hospital, London, UK.

Treatment failures with vancomycin prompted us to investigate the phenomenon of tolerance to glycopeptides in recent clinical isolates of Staphylococcus aureus. We used both MBC/MIC determinations and time- kill measurements to study tolerance to vancomycin and teicoplanin in 35 blood or heart valve isolates of S. aureus from patients with endocarditis or bacteraemia. There was generally good agreement between vancomycin tolerance indicated by an MBC:MIC ratio of > or =32 and by < or =90% kill after 6 h incubation in the presence of 20 mg/L vancomycin. However, two isolates were tolerant according to their MBC:MIC ratios but non-tolerant as judged by time-kill measurements. Seven of 15 methicillin-resistant S. aureus (MRSA) isolates but only two of 20 methicillin-susceptible ones were tolerant as judged by time- kill experiments (chi2 = 4.27 with Yates' correction, P = 0.04). Seven of the 16 isolates from patients with endocarditis were tolerant, compared with only two of the 19 isolates from patients with other conditions (chi2 = 3.43 with Yates' correction, P = 0.06). Within the endocarditis and non-endocarditis subgroups, tolerance was associated more frequently with methicillin resistance than with susceptibility, but the numbers were too small for the differences to be statistically significant. Most of the vancomycin-tolerant isolates were also tolerant to teicoplanin. We conclude that glycopeptide tolerance is a real phenomenon in S. aureus, particularly amongst MRSA isolates, and can be reliably determined by our method of time-kill analysis. Tolerance may compromise glycopeptide therapy of serious S. aureus infection and should be taken into account when deciding treatment.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. M. Traczewski, B. D. Katz, J. N. Steenbergen, and S. D. Brown
Inhibitory and Bactericidal Activities of Daptomycin, Vancomycin, and Teicoplanin against Methicillin-Resistant Staphylococcus aureus Isolates Collected from 1985 to 2007
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1735 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
K. L. Frank, J. L. del Pozo, and R. Patel
From Clinical Microbiology to Infection Pathogenesis: How Daring To Be Different Works for Staphylococcus lugdunensis
Clin. Microbiol. Rev., January 1, 2008; 21(1): 111 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. L. Frank, E. J. Reichert, K. E. Piper, and R. Patel
In Vitro Effects of Antimicrobial Agents on Planktonic and Biofilm Forms of Staphylococcus lugdunensis Clinical Isolates
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 888 - 895.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
I. Bourgeois, M. Pestel-Caron, J.-F. Lemeland, J.-L. Pons, and F. Caron
Tolerance to the Glycopeptides Vancomycin and Teicoplanin in Coagulase-Negative Staphylococci
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 740 - 743.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. L. French
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1107 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. S. Sader, T. R. Fritsche, and R. N. Jones
Daptomycin Bactericidal Activity and Correlation between Disk and Broth Microdilution Method Results in Testing of Staphylococcus aureus Strains with Decreased Susceptibility to Vancomycin.
Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2330 - 2336.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Gander, A. Kinnaird, and R. Finch
Telavancin: in vitro activity against staphylococci in a biofilm model
J. Antimicrob. Chemother., August 1, 2005; 56(2): 337 - 343.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. Asseray, C. Jacqueline, V. Le Mabecque, E. Batard, D. Bugnon, G. Potel, and J. Caillon
Activity of Glycopeptides against Staphylococcus aureus Infection in a Rabbit Endocarditis Model: MICs Do Not Predict In Vivo Efficacy
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 857 - 859.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
G. Sakoulas, P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering Jr., and G. M. Eliopoulos
Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
J. Clin. Microbiol., June 1, 2004; 42(6): 2398 - 2402.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. Cha and M. J. Rybak
Linezolid and Vancomycin, Alone and in Combination with Rifampin, Compared with Moxifloxacin against a Multidrug-Resistant and a Vancomycin-Tolerant Streptococcus pneumoniae Strain in an In Vitro Pharmacodynamic Model
Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1984 - 1987.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Gander, K. Hayward, and R. Finch
An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model
J. Antimicrob. Chemother., February 1, 2002; 49(2): 301 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
O. Kozawa, T. Uematsu, H. Matsuno, M. Niwa, K.-I. Kohno, A. Kawato, K. Takahashi, S. Nagashima, and M. Kanamaru
Pharmacokinetics of a New Parenteral Oligosaccharide Antibiotic, SCH27899 (Ziracin), in Healthy Subjects
Antimicrob. Agents Chemother., March 1, 2001; 45(3): 917 - 921.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
P. Vaudaux, P. Francois, B. Berger-Bachi, and D. P. Lew
In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus
J. Antimicrob. Chemother., February 1, 2001; 47(2): 163 - 170.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. May, C. H. Chan, A. King, L. Williams, and G. L. French
Time-kill studies of tea tree oils on clinical isolates
J. Antimicrob. Chemother., May 1, 2000; 45(5): 639 - 643.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.